We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarker Panel for Risk of Early Respiratory Failure Following Hematopoietic Cell Transplantation

By LabMedica International staff writers
Posted on 23 Mar 2022
Print article
Image: The Orbitrap Fusion Mass Spectrometer was used to identify the biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation (Photo courtesy of Thermo Fisher Scientific)
Image: The Orbitrap Fusion Mass Spectrometer was used to identify the biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation (Photo courtesy of Thermo Fisher Scientific)

Allogeneic hematopoietic cell transplantation (HCT) is a life-saving therapy used for malignant and nonmalignant diseases. However, post-HCT pulmonary complications continue to be a significant problem. When severe, pulmonary complications can result in respiratory failure (RF), affecting 10% to 23% of patients.

Currently, there is no simple blood test to guide the susceptibility to RF in the HCT recipient. Although some candidate proteomic biomarkers have been studied in the general adult population to predict the severity and mortality associated with acute respiratory distress syndrome (ARDS), little data exist on biomarkers that can predict the development of RF, particularly in children.

A team of Pediatricians and other scientists from several institutes worked with those at Riley Hospital for Children (Indianapolis, IN, USA) included in a study four cohorts (discovery, training, validation, and independent) of patients post-HCT. The team sought to identify novel biomarkers for RF, through a well-established quantitative tandem mass spectrometry–based proteomics discovery approach developed in their laboratory, by comparing plasma pooled from 15 patients with RF within 100 days post-HCT with plasma pooled from 15 patients without RF.

The scientists analyzed the samples with an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) and compared plasma obtained at day 14 post-HCT from 15 patients with RF and 15 patients without RF. Six candidate proteins, from this discovery cohort or identified in the literature, were measured by enzyme-linked immunosorbent assay in day-7 and day-14 post-HCT samples from the training (n = 213) and validation (n = 119) cohorts.

The investigators reported that of the six markers, Stimulation-2 (ST2), WAP 4-disulfide core domain protein 2 (WFDC2), interleukin-6 (IL-6), and tumor necrosis factor receptor 1 (TNFR1), measured at day 14 post-HCT, had the most significant association with an increased risk for RF in the training cohort: ST2: hazard ratio [HR], 4.5; WFDC2: HR, 4.2, IL-6: HR, 6.9; and TFNR1: HR, 6.1; and in the validation cohort: ST2: HR, 23.2) ; WFDC2: HR, 18.2; IL-6: HR, 12.2; and TFNR1: HR, 16.1; after adjusting for the conditioning regimen. Using cause-specific landmark analyses, including days 7 and 14, high plasma levels of ST2, WFDC2, IL-6, and TNFR1 were associated with an increased HR for RF in the training and validation cohorts. These biomarkers were also predictive of mortality from RF. ST2, WFDC2, IL-6 and TNFR1 levels measured early post-transplantation improve risk stratification for RF and its related mortality.

The authors concluded that high levels of ST2, WFDC2, IL-6, and TNFR1 measured as early as day 7 post-HCT are associated with the development of RF within the first 100 days post-HCT and with mortality with RF. These biomarkers offer objective data to begin to identify the highest-risk patients who may benefit from early intervention; they may also hold promise for therapeutic targets to alter the course and outcome of RF. The study was published on March 17, 2022 in the journal Blood Advances.

Related Links:
Riley Hospital for Children 
Thermo Fisher Scientific 

Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
Automated R-AST Solution
Radian BC
Molecular Diagnostic System
FlashDetect Flash48
Electrolyte Analyzer
K-Lite 5 Series

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.